hotspot -WSS

hotspot

author：knowledge 2025-09-30 08:52:23 - browse：7916

Chris O'Meara/AP

Johnson & Johnson faces a consequential new class action lawsuit — not in its role as a manufacturer of drugs, but as an employer and purchaser of prescription drugs for its workers.

Ann Lewandowski, a health care policy and advocacy director at J&J, sued her company on Monday for allegedly overpaying its pharmacy benefit manager for its employees’ medicines, citing previous STAT reporting to support some of the allegations. Those overpayments, the lawsuit alleges, ultimately come out of workers’ paychecks in the form of high health insurance premiums, higher out-of-pocket drug costs, and stunted wage growth.

In one example, J&J allegedly paid its PBM more than $10,000 for a single 90-day prescription of teriflunomide, a generic medicine for multiple sclerosis, when that same 90-day prescription could be purchased for as little as $30 elsewhere without insurance, according to the lawsuit.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Biden calls for immediate release of Niger's president amid apparent coup

focus

WSS

Discs beat pads, tampons for heavy menstrual flow, new study shows

My superpower is killing ticks

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

2 US Navy sailors arrested for allegedly spying for China

Judge rejects Trump's counterclaim against E. Jean Carroll

Germany receives 178 compensation applications from gay servicepeople over discrimination

focus

hotspot

entertainment

Trump demands the U.S. pay no more for drugs than other countries … again

What Mike Pence has said that could be used in a Donald Trump trial

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Choosing scientific sides in the fight against Alzheimer's

Medical leaders decry Supreme Court decision on affirmative action

FTX founder Sam Bankman

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Zapping the brain for stroke rehab: Pivotal clinical trial begins

New air purifier tech could be key to improving indoor air quality

More regulation could be coming for drug ads

explore

Discs beat pads, tampons for heavy menstrual flow, new study shows

Nearly two

CDC launches VaccineFinder tool to locate Covid

Travel bans should be based on evidence, not politics or fear

Gilgo Beach: Police identify another victim in serial killing investigation

Stem cell clinics for heart failure: buyer be wary

focus

knowledge

focus

knowledge